** Shares of drugmaker Vertex Pharmaceuticals VRTX.O fall 1.8% to $461 in morning trade
** Co on Monday reported Q4 profit of $3.98/shr, missing analysts' est. of $4.03/shr - as per LSEG data
** Q4 sales of co and partner CRISPR's CRSP.BN sickle-cell disease therapy, Casgevy, came in at $8 mln vs est. of $17.7 mln
** Brokerage TD Cowen says sales of Casgevy could be hurt by adoption and manufacturing-related challenges; does not expect VRTX to post billion-dollar revenues for the therapy
** VRTX forecast 2025 rev. of $11.75 bln to $12.0 bln, vs. est. of $11.84 bln
** Co said it aims to launch five new treatments by 2028, which includes a next-generation cystic fibrosis drug and its recently approved non-opioid painkiller, Journavx
** Stock has risen 11% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。